EFFECTIVENESS OF SUBCONJUNCTIVAL BEVACIZUMAB
ASSOCIATED WITH A LASER - BASED PROCEDURE IN THE
TREATMENT OF NEOVASCULAR GLAUCOMA
MARIA ALEXANDRA PREDA 1#, GHEORGHITA POPA 1#, OLIMPIU L. KARANCSI 2#*, OVIDIU MUSAT 3#, STELLA IOANA POPESCU 3#, MIHNEA MUNTEANU 1#, ZORAN POPA 4#
1Department of Ophthalmology, “Victor Babeş” University of Medicine and Pharmacy, Timisoara, Romania
2Department of Oral Implantology and Prosthetic Restorations on Implants, “Victor Babes” University of Medicine and
Pharmacy, Timisoara, Romania
3Department of Ophthalmology, “Dr. Carol Davila” Central Military Emergency University Hospital, Bucharest, Romania
4Department of Obstetrics and Gynaecology, “Victor Babes” University of Medicine and Pharmacy, Timisoara, Romania
*corresponding author: olilk@yahoo.com
#All authors have equal contribution
DownloadDownload Full Article

Abstract:
Micropulse transscleral diode laser cyclophotocoagulation (mTSCPC) is an established method of treatment for refractory
glaucoma. This study evaluates the efficacy and safety of subconjunctival bevacizumab associated with mTSCPC versus
mTSCPC alone. A number of six patients with neovascular glaucoma were treated with mTSCPC, three patients being
treated with mTSCPC alone and three patients being treated with combination of mTSCPC and subconjunctival
bevacizumab. The intraocular pressure (IOP), visual acuity, number of medications were monitored for 6 months.
Complications that include visual acuity decline, prolonged anterior chamber inflammation and ocular pain were evaluated
during the 6 months follow-up. No significant difference was found between the two groups at baseline (p = 0.82) or final
follow up (p = 1) regarding the IOP reduction; neovascularisation regression was observed only in the combined therapy
group (66.6%). Micropulse transscleral cyclophotocoagulation with diode laser is an effective method of lowering intraocular
pressure in cases of refractory glaucoma, with minimal ocular complications. Additionally, the association between mTSCPC
and subconjunctival bevacizumab resulted in neovascularisation regression and IOP reduction.






Top